Skip to main content
OpenTrials
Recruiting

NCT Number: NCT03525054

Semantic and Syntactic Computerized Analysis of Free Speech

Subtle speech disorganization could be predictive of a transition to schizophrenia of ultra-high-risk patients. The aim of our longitudinal multicenter cohort study is to identify specific linguistic markers of the psychotic transition to validate a french predictive model of this transition using computerized speech analysis techniques

Recruiting

Interested in participating?

Request Info

Key information

Age range

15 year–30 year

Sex eligibility

All sexes

Study type

Observational

Primary location

CHRU de Brest, Brest, France

Loading trial locations.

About this study

Different scales allow identification of patients at ultra-high-risk to develop psychosis. The current challenge is to identify a predictive marker of transition to schizophrenia. Language disorders, which reflect psyche, could be one of these markers. Computerized speech analysis techniques such as Latent Semantic Analysis (LSA) have already proven their reliability in schizophrenia. These techniques reveal subtle speech disorganization that would be predictive of a clinical transition of ultra-high-risk psychotic patients. A combination of semantic and syntactic analysis could accurately predict the psychotic transition. The aim of our longitudinal multicenter cohort study is to validate this predicitve model in french language as well as identifying specific linguistic markers of the psychotic transition.

The initial report including the CAARMS is completed with an audio recording from the initial medical interview. The recording will be transcribed and analyzed by computer following the method of lemmatization and vectorial analysis (LSA). An analysis of the grammatical function (number of words, rate of the various grammatical functions) will also be performed. This first analysis will emerge linguistic markers correlated to transition to psychosis that we will use to construct a predictive model for transition to schizophrenia.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Major and/or minor from 15 to 30 years old
  • Who alleged a suicidal gesture or idea or behavior that has repercussions in their emotional, social or professional life
  • If patients receive neuroleptic treatment that impairs cognitive abilities, a one-week wash-out period will be scheduled prior to assessment.
  • Affiliated with or beneficiary of a health insurance/social security system
  • Able and willing to provide written informed consent

Exclusion criteria

  • History of psychosis
  • Risk of self-harm or violence not compatible with outpatient treatment
  • QI<70 (WAIS)
  • Neurological disorder or major health problem
  • Impossibility to interrupt neuroleptic treatment for one week
  • Refusal to participate

Treatment and study plan

Primary outcomes

  1. Transition to schizophrenia

    Time frame: 2 years

    Determined from the CAARMS scale (COMPREHENSIVE ASSESSMENT OF AT RISK MENTAL STATES)

Secondary outcomes

  1. Identification of patients at "ultra high risk " for developing schizophrenia

    Time frame: Day 0

    Determined from the CAARMS scale ( COMPREHENSIVE ASSESSMENT OF AT RISK MENTAL STATES)

Study contacts

Contact information is provided by the study sponsor or research team.

Christophe LEMEY, Doctor

CONTACT

[email protected]

02 98 01 52 06

Sponsors and collaborators

Lead sponsor

University Hospital, Brest

Other

Registry information

Acronym: ASESID

Important dates

Study start
2018
Primary completion
2030
Study completion
2030
First posted
May 15, 2018
Registry last updated
Jun 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.